CompletedPhase 2

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

United States22 participantsStarted 2014-10

Plain-language summary

The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectious uveitis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosis of noninfectious uveitis * diagnosis of macular edema associated with noninfectious uveitis Exclusion Criteria: * any ocular trauma within the immediate 6 months prior to treatment * any photocoagulation or cryotherapy in the 6 months prior to treatment * any IVT injection of anti-VEGF treatment in the 2 months prior to treatment * any eye diseases other than uveitis and ME that could compromise central visual acuity * any previous suprachoroidal injection of triamcinolone acetonide in the study eye

What they're measuring

Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following Uveitis

Timeframe: 2 months

Trial details

NCT IDNCT02255032

SponsorClearside Biomedical, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-12

Results submitted2021-01-18

View on ClinicalTrials.gov More Uveitis trials